Content
03/28/2020 Menlo Park, CA USA
ReCode Therapeutics completed $80 million Series A Round funding. Investors include OrbiMed Advisors (lead), Colt Ventures (lead), MPM BioImpact, Osage University Partners, Vida Ventures.
#Biotech  #Life Science  
About
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
Startup
ReCode Therapeutics
https://recodetx.com Claim Profile
Location:
Menlo Park, CA USA
Sector:
Biotech
Life Science
Download StockFan App Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.